In conclusion, circadian-timed ZT 13 bromocriptine administration to hypertensive, metabolic syndrome SHR rats reduced biomarkers of aortic ROS/RNS stress and circulating oxidative stress coupled to the reversal of the metabolic syndrome and reductions in MBH NPY and AgRP mRNA expressions, as well as influenced several MBH genes associated with neuronal plasticity, while ZT 19 bromocriptine administration was largely without effect on the vast majority of these test parameters. This evidence concerns the gene NPY and metabolic syndrome.